Huntington disease

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 5, 1998, Pages 369-384

  Vonsattel, Jean Paul G ^a,b   DiFiglia, Marian ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Neuroscience Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMIC ACID; HUNTINGTIN;

ARTICLE; BASAL GANGLION; CHROMOSOME 4; CLINICAL FEATURE; HUMAN; HUNTINGTON CHOREA; NEOSTRIATUM; NEUROPATHOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL;

EID: 0031837533     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199805000-00001     Document Type: Article

References (60)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83
2. Myers RH, MacDonald ME, Koroshetz WJ, et al. De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nature Genetics 1993;5:168-73
3. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: Neurologic features and functional decline. Neurology 1986;36:244-49
4. Harper PS. Huntington's disease. Major problems in neurology (31). 2nd edition. London: W.B. Saunders Company Ltd., 1996
5. Folstein SE. Huntington's disease. A disorder of families. London: The Johns Hopkins University Press Ltd., 1990
6. Persichetti F, Ambrose CM, Ge P, et al. Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Molecular Medicine 1995;1: 374-83
7. Persichetti F, Srinidhi J, Kanaley L, et al. Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiol Disease 1994;1:159-66
8. Rubinsztein DC, Leggo J, Coles R, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 1996;59:16-22
9. Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401-6
10. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994;44:1533-36
11. Graybiel AM, Aosaki T, Flaherty AW, Kimura M. The basal ganglia and adaptive motor control. Science 1994;265:1826-31
12. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. TINS 1989;12:366-75
13. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. TINS 1990; 13:266-71
14. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 1990;27:357-65
15. Matsumura M, Tremblay L, Richard H, Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995;65: 59-70
16. Goldman-Rakic PS. Cytoarchitectonic heterogeneity of the primate neostriatum: Subdivision into island and matrix cellular compartments. J Comp Neurol 1982;205:398-413
17. Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic: II. Patch-and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987;7:3915-34
18. Ferrante RJ, Kowall NW, Richardson EPJr. Cellular composition of striatal patch and matrix compartments in Huntington's disease [abstract]. Society of Neuroscience 1989;15:935
19. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995;54: 105-20
20. Graveland GA, Williams RS, DiFiglia M. A Golgi study of the human neostriatum: Neurons and afferent fibers. J Comp Neurol 1985;234:317-33
21. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T. Matabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders? TINS 1996;19:267-71
22. Weeks RA, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996;40:49-54
23. Vonsattel J-P, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-77
24. de la Monte SM, Vonsattel JP, Richardson EP Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988;47:516-25
25. Myers RH, Vonsattel JP, Paskevich PA, et al. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol 1991;50:729-42
26. Vonsattel J-P, Myers RH, Bird ED, Ge P, Richardson EP Jr. Maladie de Huntington: Sept cas avec îlots néostriataux relativement préservés. Rev Neurol 1992;148:107-16
27. Braak H, Braak E. Allocortical involvement in Huntington's disease. Neuropathology and Applied Neurobiology 1992;18:539-47
28. Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 1991;41:1117-23
29. Cudkowicz M, Kowall NW. Degeneration of pyramidal projection neurons in Huntingon's disease cortex. Ann Neurol 1990;27:200-204
30. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 1991;133:257-61
31. Markham CH, Knox JW. Observations on Huntington's chorea in childhood. J Pediatr 1965;67:46-57
32. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntingons' disease. Science 1985;227:770-73
33. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988;85:5733-37
34. Sapp E, Ge P, Aizawa H, et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 1995;64:397-404
35. Richfield EK, Maguire-Zeiss KA, Cox C, Gilmore J, Voorn P. Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann Neurol 1995;37:335-43
36. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 1987;46:12-27
37. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-71
38. Koh J-Y, Peters S, Choi DW. Neurons containing NADPH-Diaphorase are selectively resistant to quinolinate toxicity. Science 1986;234:73-76
39. Beal MF, Brouillet E. Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13: 4181-92
40. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996;39:385-89
41. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? TINS 1993;16:125-31
42. Mazurek MF, Garside S, Beal MF. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann Neurol 1997;41:540-47
43. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntingon's disease. Ann Neurol 1996;39: 132-36
44. Penney JB, Vonsattel J-P, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-92
45. Landwehrmeyer GB, McNeil SM, Dure LS IV, et al. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Ann Neurol 1995;37:218-30
46. Gutekunst, C-A, Levey, AI, Heilman, GJ, et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci USA 1995;92:8710-14
47. Ferrante RJ, Gutekunst C-A, Persichetti F, et al. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci 1997;17:3052-63
48. DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075-81
49. Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntington's disease gene homolog (Hdh). Science 1995;269: 407-10
50. White JK, Auerbach W, Duyao MP, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nature Genetics 1997;17:404-10
51. Aronin N, Chase K, Young C, et al. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron 1995;15:1193-1201
52. Sapp E, Schwarz C, Chase K, et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997;42: 604-12
53. Gourfinkel-An I, Cancel G, Trottier Y, et al. Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann Neurol 1997;42:712-19
54. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neuntes in brain. Science 1997;277:1990-93
55. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-48
56. Burke JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med 1996;2:347-50
57. Li X-J, Li S-H, Sharp AH, et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995;378: 398-402
58. Perutz MF, Johnson T, Suzuki M, Finch T. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 1994;91:5355-58
59. Robitaille Y, Lopes-Cendes I, Becher M, Rouleau G, Clark AW. The neuropathology of CAG repeat diseases: Review and update of genetic and molecular features. Brain Pathology 1997;7:901-26
60. Ordway JM, Tallaksen-Greene S, Gutekunst C-A, et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressvie late onset neurological phenotype in the mouse. Cell 1997; 91:753-63